Swing Therapeutics Selects Curavit to Provide Virtual Trial Site Services for New Digital Fibromyalgia Therapeutics Study

BOSTON, June 28, 2022 /PRNewswire/ — Curavit clinical research, a virtual contract research organization (VCRO), has been selected by a digital therapy company, Therapeutic Swing, to be a virtual site for its pivotal trial of an experimental digital therapy (DTx) for fibromyalgia. Curavit will remotely recruit, screen, consent and enroll Swing’s participants PROSPER-FM randomized clinical trial through United States. Curavit will then manage participants throughout the 12-week clinical trial. By removing physical and geographic barriers to trial participation and execution, Curavit can scale rapidly and improve patient recruitment by at least 10x compared to a traditional trial, thereby accelerating trial execution.

Fibromyalgia is a chronic, debilitating pain that affects more than 10 million Americans. It is characterized by generalized musculoskeletal pain often accompanied by fatigue, sleep disturbances, memory and mood. Swing developed its digital therapy with the goal of providing an accessible behavioral therapy option that can be used alongside medication, physical therapy, and other standard treatments.

“We are focused on good patient recruitment,” said Mike RosenbluthPhD, Chief Executive Officer of Swing, who recently announcement a $10M Series A funding round. “Curavit’s virtual service model allows us to effectively recruit participants representative of the entire patient population. It solves a huge challenge and will be key to rapidly building the evidence needed to bring effective digital therapy to millions of people with chronic conditions.

Swing marks the 10 of Curavite DTx client signed in less than six months, trending in line with booming global DTx market expected to reach $13.1 billion by 2026from $3.4 billion in 2021. Curavit’s decentralized clinical trial (DCT) expertise makes the company well-suited to support prescription and non-prescription DTx studies. Basically, there are no physical logistics with a DTx – no shipping, storage, chain of custody, cold storage or biohazards, and endpoints can often be captured in the DTx app itself, naturally aligning DCTs with DTx studies.

“Swing is committed to developing scientifically backed digital treatments and evidence to clinically validate their use in the real world, making representative patient engagement essential,” said Joel Morse, co-founder and CEO of Curavit. “Our operating model prioritizes patient recruitment and removes geographic boundaries to expand the pool without the expense of physical infrastructure. With zero physical visits to site as well, patients are less overburdened and more likely to stick on trial for the duration.”

About Curavit

Curavit clinical research is a full-service virtual contract research organization (VCRO) focused on the design and execution of digital decentralized clinical trials (DCTs). Founded in 2020 by experts with decades of experience in technology and clinical research, Curavit leverages emerging technologies in digital health, cloud computing and data science to recruit, engage and monitor diverse populations patients without borders and offer trials to patients in the cloud. . Curavit’s first digital DCTs improve timelines, reduce costs, generate real data and increase patient access to more effective therapies in representative populations. Visit www.curavitclinicalresearch.com.

SOURCE Curavit Clinical Research

Comments are closed.